The demo achieved the two its Principal endpoints, with semaglutide 2.4 mg demonstrating statistically important and excellent advancements in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis without any worsening of liver fibrosis in people with MASH when compared to placebo.1Excellent luck! Strategy yo